Invion (IVIXF)
OTHER OTC:IVIXF
IVIXF Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EST
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.04
Previous CloseN/A
Volume2.00
Average Volume (3M)0.00
Market Cap
$4.64M
Enterprise Value$6.79M
Total Cash (Recent Filing)$137.54K
Total Debt (Recent Filing)$627.68K
Price to Earnings (P/E)―
Beta-3.00
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding96,965,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market Cap1.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.27
Enterprise Value/Ebitda-1.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageNo reported debt reduces fixed financial obligations and interest burden, preserving cash for R&D and clinical programs. A debt-free capital structure improves resilience across funding cycles and gives management flexibility to negotiate licensing or partnership financing without servicing debt.
Proprietary Technology & PartnershipsA proprietary Photodynamic Therapy platform combined with collaborations with leading research institutions creates durable IP and clinical expertise advantages. Partner-funded development and licensing pathways can lower direct R&D expense and increase commercialization chances if clinical milestones are met.
Improving Free Cash Flow TrendAn improvement in free cash flow year-over-year signals early operational leverage and better cash conversion dynamics. If sustained, this trend can extend the company runway, reduce dependency on dilutive capital raises, and support continued investment in key development programs.
Bears Say
Revenue CollapseReporting zero revenue in FY2025 alongside a substantially larger net loss indicates the company failed to monetize its programs. This severely limits internal funding capacity, heightens reliance on external financing, and raises long-term commercialization and viability risk if revenue generation is not restored.
Persistent Cash BurnConsistent negative operating cash flow and a sizable FY2025 outflow demonstrate ongoing cash burn to fund operations. Durable business progress requires positive cash generation; sustained deficits threaten trial continuity, strain partner negotiations, and increase the probability of dilutive or unfavorable financing.
Shrinking Equity & AssetsMaterial declines in equity and total assets materially reduce the company’s financial cushion and strategic optionality. With a thinner balance sheet, access to non-dilutive financing or secured debt is harder, increasing dilution risk and limiting ability to absorb setbacks or scale late-stage development.
Invion News
IVIXF FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was $0.04 and its highest was $0.04 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is $4.64M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 140 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.03.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 96,965,320 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in IVIXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
-150.48%
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Ownership Overview
Options Prices
Currently, No data available
---